Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen
Background: Breast cancer (BC) is a heterogeneous disease for which the commonly used chemotherapeutic agents primarily include the anthracyclines (doxorubicin, epirubicin), microtubule inhibitors (paclitaxel, docetaxel, eribulin), and alkylating agents (cyclophosphamide). While these drugs can be h...
Main Authors: | Sugandha Bhatia, Tony Blick, Cletus Pinto, Mark Waltham, James Monkman, Ekaterina Ivanova, Pamela M. Pollock, Shivashankar H. Nagaraj, Adrian P. Wiegmans, Izhak Haviv, Kaylene J. Simpson, Erik W. Thompson |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/5/1123 |
Similar Items
-
Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01) -
Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01) -
Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
by: E V Artamonova
Published: (2017-09-01) -
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
by: Vera A Gorbunova, et al.
Published: (2019-03-01) -
Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor
by: Yasuhiro Fujisawa, et al.
Published: (2018-03-01)